AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27804203
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment experience
Trial: 21359522
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg) plus rebamipide (300 mg)
Trial: 11876701
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg)
Trial: 19843657
Drug: Lu 35‐138
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu 35‐138 (I(Kr)‐blocking antipsychotic compound)
Trial: 15214594
Drug: Postoperative 5-FU-based
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative 5-FU-based chemotherapy combined with irradiation
Trial: 15214594
Drug: Preoperative combined-modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative combined-modality therapy
Trial: 15214594
Drug: Oral capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine (Xeloda) as a radiation enhancer
Trial: 9105077
Drug: Inspiratory elastic
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory elastic load of 18 cm H2O/L
Trial: 2630295
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mg) in decaffeinated coffee
Trial: 235013
Drug: Pimozide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (mean 18.8 mg/day for 6 weeks)
Trial: 25228137
Drug: Ivermectin 1%
RxNorm normalized name: IVERMECTIN 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 1% cream (IVM 1%) once daily
Trial: 25228137
Drug: Metronidazole 0.75%
RxNorm normalized name: METRONIDAZOLE 0.75% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.75% cream (MTZ 0.75%) twice daily
Trial: 21531671
Drug: Actual Reiki
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actual Reiki therapy
Trial: 19750999
Drug: Prophylactic radiation
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic radiation therapy (700 cGy)
Trial: 15607618
Drug: cerivastatin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cerivastatin (0.3 mg/day)
Trial: 15607618
Drug: candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan (8 mg/day)
Trial: 15607618
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (24 normocholesterolemic subjects without any therapy)
Trial: 8445152
Drug: 50 mU
RxNorm normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mU biosynthetic human growth hormone (r‐hGH) bolus
Trial: 8445152
Drug: 80 mU/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mU/h iv infusion of r‐hGH
Trial: 24419019
Drug: Electromyography-triggered neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyography-triggered neuromuscular stimulation and mirror therapy (ETMS-MT)
Trial: 18562328
Drug: Anthracycline-docetaxel-based sequential
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracycline-docetaxel-based sequential or concurrent chemotherapy
Trial: 12437859
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care patients received bimonthly protective treatment and twice-daily chlorhexidine mouthrinses to treat gingivitis
Trial: 12437859
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group subjects received professional dental protective treatment and checkups at baseline, 6 months, and 1 year, plus dental care
Trial: 10851564
Drug: Low-dose fosinopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fosinopril (10 mg/d)
Trial: 28461283
Drug: Minimal-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-treatment control
Trial: 17360294
Drug: 10-g Semmes-Weinstein
RxNorm normalized name: lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-g Semmes-Weinstein monofilament test
Trial: 15347374
Drug: Injective immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injective immunotherapy with a maintenance dose of 7.2 microg of Amb a 1 administered at 4-week intervals
Trial: 21439539
Drug: hs-CRP >2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP >2 mg/L and BMS
Trial: 21439539
Drug: hs-CRP >2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP >2 mg/L and DES
Trial: 21439539
Drug: hs-CRP ≤2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP ≤2 mg/L and BMS
Trial: 21439539
Drug: hs-CRP ≤2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP ≤2 mg/L and DES
Trial: 21439539
Drug: BMS +
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS + CRP ≤2 mg/L
Trial: 31341122
Drug: Implant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant treatment
Trial: 8497701
Drug: Methotrexate 30
RxNorm normalized name: METHOTREXATE 30MG/0.6ML AUTO INJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 30 mg week-1
Trial: 29138275
Drug: 1-h blood
RxNorm normalized name: SUS SCROFA BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h blood glucose measurement (≥8.6 mmol/L)
Trial: 29138275
Drug: 2-h blood
RxNorm normalized name: SUS SCROFA BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-h blood glucose measurement (≥7.8 mmol/L)
Trial: 20886788
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with western medicine (Simvastatin, Glipizide XL, Felodipine sustained-release tablets)
Trial: 20886788
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine only (Simvastatin, Glipizide XL, Felodipine sustained-release tablets)
Trial: 22441222
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between groups after treatment
Trial: 10981087
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin therapy in patients with hypertension
Trial: 8877020
Drug: Metamizol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol 25 mg kg‐1
Trial: 8877020
Drug: Pethidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.4 mg kg‐1
Trial: 1890910
Drug: Nicardipine (60‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (60‐120 mg daily)
Trial: 1890910
Drug: Propranolol (120‐240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120‐240 mg daily)
Trial: 6366719
Drug: Cimetidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (600 mg/m2 body surface/day for 4 months)
Trial: 20038244
Drug: Fluconazole (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (1200 mg per day) alone
Trial: 20038244
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluconazole (1200 mg per day) and flucytosine (100 mg/kg per day) followed by fluconazole (800 mg per day)
Trial: 12004166
Drug: Continuous low-level
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low-level heat wrap therapy (40 C, 8 hours/day)
Trial: 369652
Drug: Other two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other two agents (Bendrofluazide and Spironolactone)
Trial: 31208509
Drug: High-dose caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caffeine (10 mg/kg maintenance dose after 20 mg/kg loading dose)
Trial: 31208509
Drug: Low-dose caffeine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose caffeine (5 mg/kg maintenance dose after 20 mg/kg loading dose)
Trial: 31208509
Drug: High-dose caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caffeine
Trial: 26731724
Drug: Temsirolimus (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25mg weekly IV infusions)
Trial: 17122357
Drug: Intranasal leptin
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal leptin delivery; superpotent leptin-receptor agonists; manipulation of SOCS-3, PTP-1B, ciliary neurotrophic factor; traditional interventions for weight loss.
Trial: 17122357
Drug: Activation of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activation of melanocortin receptors; activation of 5-HT2C and 5-HT1B receptors.
Trial: 17122357
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of neuropeptide Y, melanin-concentrating hormone, ghrelin, and endocannabinoids.
Trial: 10543929
Drug: Inogatran (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (low molecular mass direct thrombin inhibitor)
Trial: 2201795
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (100 million units) recombinant alpha‐2b‐interferon
Trial: 2201795
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (10 million units) recombinant alpha‐2b‐interferon
Trial: 189334
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ACTH 4-10
Trial: 189334
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg ACTH 4-10
Trial: 31288177
Drug: VEGF-A165/bFGF plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF-A165/bFGF plasmid (VIF) administered via electromechanical system NOGA-guided intramyocardial injections into ischemic regions.
Trial: 31288177
Drug: Placebo plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plasmid injections.
Trial: 28374466
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA) - 156 ml of a mixture of 0.2% ropivacaine + 30 mg ketorolac + 0.5 mg (5 ml) adrenaline
Trial: 28374466
Drug: Saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline and intravenous ketorolac (Control)
Trial: 7582282
Drug: Inhaled wild‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled wild‐type rhinovirus 16 (RV16) administered at a total dose of 3 x 10(4) TCID50
Trial: 7582282
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in equal doses into both nostrils
Trial: 1782971
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (0.8, 1.6, and 3.2 mg/day)
Trial: 1782971
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (5, 10, and 20 mg/day)
Trial: 1782971
Drug: Both inhaled
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both inhaled budesonide and oral prednisolone
Trial: 28183288
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint therapy (Sp-Tx)
Trial: 21963104
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin chloride topical gel (OTG)
Trial: 19257867
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard therapy for IHD)
Trial: 17907859
Drug: self‐help involvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐help involvement during treatment
Trial: 17907859
Drug: self‐efficacy and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self‐efficacy and commitment to abstinence 3 months after treatment
Trial: 9676755
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) administered intramuscularly at 10 AM
Trial: 9676755
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) administered intramuscularly at 6 PM
Trial: 9676755
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of MTX administration times (10 AM vs 6 PM)
Trial: 29643163
Drug: Intratracheal Dex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal Dex (0.5 µg/kg)
Trial: 29643163
Drug: Intravenous Dex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Dex (0.5 µg/kg)
Trial: 29643163
Drug: Control (Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Intravenous saline)
Trial: 28333551
Drug: 6-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week group program of 2-hour weekly sessions addressing mindfulness of food choices facilitated by a trained dietitian and social worker.
Trial: 25883031
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human soluble thrombomodulin (rhTM) administration
Trial: 25883031
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rhTM administration)
Trial: 17199537
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration (GTR) therapy using non-resorbable expanded polytetrafluoroethylene membranes
Trial: 17199537
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration (GTR) therapy using bioabsorbable barriers
Trial: 11559318
Drug: Trimethoprim-sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice daily for 2 weeks, followed by 80 mg trimethoprim and 400 mg sulfamethoxazole twice daily for 5.5 months
Trial: 3169108
Drug: SR verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR verapamil 240 mg tablets administered every 12 h for 6 consecutive weeks
Trial: 3169108
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every 12 h for 6 consecutive weeks
Trial: 21439962
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition for 30 days
Trial: 12738159
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 600 microg
Trial: 12738159
Drug: Combined rectal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined rectal groups (400 and 600 microg)
Trial: 12738159
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol (both doses)
Trial: 8797943
Drug: Iodixanol (Visipaque,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (Visipaque, 320 mgI/ml)
Trial: 8797943
Drug: Iopamidol (Solutrast,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (Solutrast, 370 mgI/ml)
Trial: 6237623
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg three times a day
Trial: 6237623
Drug: Captopril 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 37.5 mg twice daily
Trial: 6237623
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg three times a day
Trial: 6822143
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg twice daily
Trial: 6237623
Drug: Hydrochlorothiazide and
RxNorm normalized name: hydrochlorothiazide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide and Captopril combination
Trial: 29447773
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor only
Trial: 29447773
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (DAPT + oral anticoagulant)
Trial: 29447773
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) only
Trial: 29447773
Drug: OAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC plus P2Y12 inhibitor
Trial: 29447773
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents without OAC
Trial: 25011657
Drug: SMS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS group (received 2 text messages twice a day for 12 weeks)
Trial: 22747980
Drug: Intramyocardial CD133(+)
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial CD133(+) bone marrow stem cell injection in combination with coronary artery bypass grafting
Trial: 7925204
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide (800 micrograms kg‐1 in two divided doses)
Trial: 24366980
Drug: LBR-101 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBR-101 (any dose)
Trial: 24366980
Drug: LBR-101 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBR-101 (1000 mg or higher)
Trial: 10102953
Drug: Budesonide 15
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 15 mg/day
Trial: 10102953
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg/day
Trial: 10102953
Drug: Budesonide 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 4.5 mg b.d.
Trial: 7805221
Drug: Encainide, flecainide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide, flecainide, and moricizine at two different dose levels (CAST-I); Moricizine alone at three dose levels (CAST-II).
Trial: 27246522
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (2.7 g of long-chain n-3 polyunsaturated fatty acids)
Trial: 22935168
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (OLAI)
Trial: 14985864
Drug: Standardized uptake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized uptake value (SUV) images acquired from 30 to 35 min after FMZ administration
Trial: 7653818
Drug: Ropivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (5 mg/mL)
Trial: 7653818
Drug: Bupivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (5 mg/mL)
Trial: 314392
Drug: Fenbufen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenbufen (500 mg capsules)
Trial: 314392
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (750 mg capsules)
Trial: 27535352
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg clonidine orally
Trial: 26448622
Drug: tPA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA (50 mg Alteplase)
Trial: 23357838
Drug: Probenecid (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (500 mg 4 times daily for 6 days)
Trial: 15679255
Drug: Gemcitabine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (specific dosage and duration not mentioned)
Trial: 15679255
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiotherapy and gemcitabine (specific details not mentioned)
Trial: 8799512
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 20 mg sublingual
Trial: 8799512
Drug: Nifedipine (NIF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NIF) 10 mg
Trial: 8799512
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 20 mg orally twice daily